Media
Media
Our latest announcements
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
05/12/2024
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
03/12/2024
Hansa Biopharma to Attend Jefferies London Healthcare Conference
13/11/2024
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
30/10/2024
Media articles
Insights
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Addressing barriers to gene therapy treatment
31/01/2024
Global Corporate Affairs
Stephanie Kenney
Vice President Global Corporate Affairs
Email: media@hansabiopharma.com